MA40875B1 - 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux - Google Patents

2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux

Info

Publication number
MA40875B1
MA40875B1 MA40875A MA40875A MA40875B1 MA 40875 B1 MA40875 B1 MA 40875B1 MA 40875 A MA40875 A MA 40875A MA 40875 A MA40875 A MA 40875A MA 40875 B1 MA40875 B1 MA 40875B1
Authority
MA
Morocco
Prior art keywords
diamino
quinoline
substituted
anticancer agents
new anticancer
Prior art date
Application number
MA40875A
Other languages
English (en)
Other versions
MA40875A (fr
Inventor
Firas Bassissi
Antoine Beret
Sonia Brun
Jérôme Courcambeck
Clarisse Dubray
Gregory Nicolas
Philippe Halfon
Original Assignee
Genoscience Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genoscience Pharma Sas filed Critical Genoscience Pharma Sas
Publication of MA40875A publication Critical patent/MA40875A/fr
Publication of MA40875B1 publication Critical patent/MA40875B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La présente invention concerne de nouveaux dérivés de 2-amino primaire-4-amino secondaire-quinoléine, leur fabrication, des compositions pharmaceutiques les comprenant et leur utilisation en tant que médicaments. Les composés actifs de la présente invention sont utiles pour le traitement et la prévention de maladies prolifératives néoplasiques et non néoplasiques.
MA40875A 2014-10-31 2015-10-26 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux MA40875B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073325P 2014-10-31 2014-10-31
EP15837091.6A EP3212629B1 (fr) 2014-10-31 2015-10-26 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
PCT/IB2015/002438 WO2016067112A1 (fr) 2014-10-31 2015-10-26 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux

Publications (2)

Publication Number Publication Date
MA40875A MA40875A (fr) 2017-09-06
MA40875B1 true MA40875B1 (fr) 2019-01-31

Family

ID=55404745

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40875A MA40875B1 (fr) 2014-10-31 2015-10-26 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux

Country Status (34)

Country Link
US (1) US10722505B2 (fr)
EP (1) EP3212629B1 (fr)
JP (1) JP6588546B2 (fr)
KR (1) KR102548547B1 (fr)
CN (1) CN107148416B (fr)
AU (1) AU2015338844B2 (fr)
CA (1) CA2965262C (fr)
CL (1) CL2017001073A1 (fr)
CO (1) CO2017007325A2 (fr)
CR (1) CR20170177A (fr)
CY (1) CY1121326T1 (fr)
DK (1) DK3212629T3 (fr)
DO (1) DOP2017000107A (fr)
EA (1) EA037119B1 (fr)
EC (1) ECSP17026748A (fr)
ES (1) ES2707125T3 (fr)
GE (1) GEP20207108B (fr)
HR (1) HRP20190107T1 (fr)
IL (1) IL251775B (fr)
LT (1) LT3212629T (fr)
MA (1) MA40875B1 (fr)
MY (1) MY193740A (fr)
NI (1) NI201700052A (fr)
PE (1) PE20191142A1 (fr)
PH (1) PH12017500810A1 (fr)
PL (1) PL3212629T3 (fr)
PT (1) PT3212629T (fr)
RS (1) RS58328B1 (fr)
SG (1) SG11201703479SA (fr)
SI (1) SI3212629T1 (fr)
TN (1) TN2017000168A1 (fr)
TR (1) TR201900148T4 (fr)
UA (1) UA122062C2 (fr)
WO (1) WO2016067112A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6969800B2 (ja) * 2016-05-04 2021-11-24 ジェノシアンス ファルマ 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
US11065265B2 (en) 2018-05-18 2021-07-20 Spes Pharmaceuticals Inc. Compositions of fosaprepitant and methods of preparation
EP3620164A1 (fr) 2018-09-05 2020-03-11 Genoscience Pharma SAS 2,4 diamino-quinoline substituée en tant que nouveau médicament destiné à la fibrose, l'autophagie et des maladies liées aux cathepsines b (ctsb), l (ctsl) et d (ctsd)
WO2020092528A1 (fr) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Composés 6-azabenzimidazole substitués ayant une activité inhibitrice de hpk1
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
EP3972695A1 (fr) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
WO2022033459A1 (fr) * 2020-08-10 2022-02-17 萧乃文 Utilisation de médicament double non-oncologique dans la préparation d'une composition pharmaceutique pour le traitement du cancer
CN112375081B (zh) * 2020-11-23 2022-04-12 中国医学科学院医药生物技术研究所 具有抑制CDK4、6或9活性的吡咯[2,3-d]嘧啶衍生物及其制备方法和应用
CN112876673B (zh) * 2021-01-25 2021-12-24 山东大学 一种pH响应性纳米共聚物载体及其制备方法和应用
EP4349336A1 (fr) 2022-10-04 2024-04-10 Genoscience Pharma Combinaison de composés 2,4-diamino-quinoléine substitués et d'inhibiteurs de mek pour une utilisation dans le traitement de cancers du foie

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
US7759336B2 (en) 2002-12-10 2010-07-20 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compounds and medicinal use thereof
EP1601357A4 (fr) * 2003-03-10 2007-10-03 Schering Corp Inhibiteurs de kinase heterocycliques : procedes d'utilisation et de synthese
SG10201705662WA (en) * 2013-01-15 2017-08-30 Incyte Corp Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
BR112015023948A2 (pt) * 2013-03-18 2017-07-18 Genoscience Pharma composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer

Also Published As

Publication number Publication date
CA2965262A1 (fr) 2016-05-06
RS58328B1 (sr) 2019-03-29
DK3212629T3 (en) 2019-02-18
ECSP17026748A (es) 2018-03-31
TN2017000168A1 (en) 2018-10-19
ES2707125T3 (es) 2019-04-02
NI201700052A (es) 2017-09-11
CA2965262C (fr) 2023-03-14
LT3212629T (lt) 2019-01-10
CN107148416B (zh) 2020-05-05
PL3212629T3 (pl) 2019-05-31
US10722505B2 (en) 2020-07-28
EP3212629A1 (fr) 2017-09-06
MY193740A (en) 2022-10-27
EA201790949A1 (ru) 2018-02-28
EA037119B1 (ru) 2021-02-09
CR20170177A (es) 2017-09-19
SG11201703479SA (en) 2017-05-30
BR112017018637A2 (pt) 2022-07-05
PH12017500810A1 (en) 2017-10-02
PE20191142A1 (es) 2019-09-02
MA40875A (fr) 2017-09-06
GEP20207108B (en) 2020-05-11
AU2015338844B2 (en) 2019-09-19
KR102548547B1 (ko) 2023-06-27
TR201900148T4 (tr) 2019-02-21
UA122062C2 (uk) 2020-09-10
AU2015338844A1 (en) 2017-05-04
CL2017001073A1 (es) 2018-01-12
PT3212629T (pt) 2019-02-04
CN107148416A (zh) 2017-09-08
WO2016067112A1 (fr) 2016-05-06
EP3212629B1 (fr) 2018-10-24
CO2017007325A2 (es) 2017-10-20
DOP2017000107A (es) 2017-09-15
IL251775B (en) 2020-07-30
SI3212629T1 (sl) 2019-02-28
NZ731345A (en) 2023-09-29
JP2017538673A (ja) 2017-12-28
GEAP202014494A (en) 2020-01-27
KR20170077160A (ko) 2017-07-05
JP6588546B2 (ja) 2019-10-09
US20190314359A1 (en) 2019-10-17
IL251775A0 (en) 2017-06-29
HRP20190107T1 (hr) 2019-03-08
CY1121326T1 (el) 2020-05-29

Similar Documents

Publication Publication Date Title
MA40875B1 (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EA201892666A1 (ru) 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
PH12019501034A1 (en) New anthelmintic quinoline-3-carboxamide derivatives
NZ710854A (en) Quinolines derivatives as novel anticancer agents
EA201792047A1 (ru) Новые соединения
MA39783A (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MX2020001403A (es) Nuevos derivados de quinolina.
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
CY1122441T1 (el) Καινοτομες ενωσεις και συζευγματα κρυπτοφυκινης, η παρασκευη τους και η θεραπευτικη χρηση τους
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
EA201990400A1 (ru) Соединения и композиции и их применение
EA202090414A1 (ru) Соединения и их применение
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
MY201535A (en) Therapeutic compounds
EA202191478A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202190588A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
MA39337B1 (fr) Modulateurs de pyrazines de gpr6
MX2021006490A (es) Compuestos heteroaromaticos como inhibidores de vanina.
EA201891680A1 (ru) Производные индана в качестве модуляторов mglur7
WO2017168454A3 (fr) Nouveaux composés utilisés comme inhibiteurs de btk
MA39533B1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MX2018003564A (es) 1,4-benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cancer.
EA201790795A1 (ru) СОЕДИНЕНИЯ 4Н-ПИРИДО[1,2-a]ПИРИМИДИН-4-ОНА
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses